AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $89.32 million.

Fiscal 2018 Fourth Quarter Highlights

• Net sales of $88.3 million, an increase of 1.6% year over year
• Gross margin expanded 500 basis points year over year to 53.7%
• GAAP EPS of $0.06 per share; adjusted EPS of $0.20 per share
• Operating cash flow of $23.8 million; free cash flow of $23.0 million

Full-Year 2018 Highlights

• Net sales of $344.3 million, a decrease of 1.5% year over year
• Gross margin expanded 100 basis points year over year to 51.4%
• GAAP EPS of $0.44 per share; adjusted EPS of $0.74 per share
• Operating cash flow of $41.3 million; free cash flow of $38.9 million

“Our quarterly and full-year results showed further improvement in our operational outcomes, continuing our path to sustainable long-term growth. We are very pleased with our year-over-year gross margin expansion and solid profitability, as well as our consistent free cash flow generation,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Our Oncology ablation systems, AngioVac thrombus management product, and Fluid Management family of products are each examples of where we are well positioned to win and grow the value of the Company. We will continue to actively focus on pursuing our portfolio optimization strategy, which includes both internal and external growth opportunities. We will look to augment those areas where we currently have a product family foundation with additional opportunities to win, driving sustainable long-term revenue growth.”

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.